Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
RESEARCH TOOLSreports
Holding ACRS?
Track your performance easily
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)991.16K
Market Cap
$267.55M
Enterprise Value-$42.92M
Total Cash (Recent Filing)$137.22M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Feb 20, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding107,018,740
10 Day Avg. Volume1,097,346
30 Day Avg. Volume991,164
Standard Deviation0.41
R-Squared0.00507
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.62
Price to Cash Flow (P/CF)2.00
P/FCF Ratio2.00
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-1.59
Enterprise Value/Gross Profit-3.26
Enterprise Value/Ebitda0.75
Forecast
1Y Price Target
$10.00Price Target Upside298.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Highlights Drug Progress and Financial Strength
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAnalyst's recommendation for Aclaris Therapeutics Inc. has been upgraded to Outperform, indicating strong confidence in the company's potential.
Market PotentialBSI-045B could generate billions of dollars in sales across solely the U.S. and European Union markets in only the chronic asthma and atopic dermatitis (AD) indications.
Pipeline DevelopmentThe acquisition of worldwide rights to two in-licensed biologics, BSI-045B and BSI-502, is expected to strengthen Aclaris Therapeutics Inc.'s immunology-focused pipeline.
Bears Say
Clinical And Regulatory RisksThere are clinical, regulatory, and commercial risks associated with Aclaris Therapeutics' pipeline products.
Strategic Review And Disappointing TrialsACRS initiated a company-wide strategic review following disappointing data from zunsemetinib in rheumatoid arthritis and hidradenitis suppurativa, where both trials failed to achieve primary and key secondary endpoints.
Uncertain OutlookOverall, the analysis remains on the sidelines pending any further updates on the strategic review, early data from the POC study of ATI-2138 in AD, and progress regarding strategic partnerships.
---
Ownership Overview
29.40% Insiders
4.88% Mutual Funds
0.42% Other Institutional Investors
59.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.95 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $267.55M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.006 by -$0.104.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 107,018,740 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.006. Following the earnings report the stock price went up 1.802%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 0.
---
Aclaris Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (298.41% Upside)
$10.00 (298.41% Upside)
Hedge Fund Trend
Decreased
By 434.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 95.4%
Last 30 Days ▲ 95.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.37%
12-Months-Change
Fundamentals
Return on Equity
-25.83%
Trailing 12-Months
Asset Growth
-16.47%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
ACRS Company Deck
---
ACRS Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Read More>---
ACRS Stock 12 Month Forecast
Average Price Target
$10.00
▲(298.41% Upside)
Technical Analysis
AnaptysBio
―
Chimerix
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Kura Oncology
―
Rigel
―
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-31.32%
reiterated a buy rating last month
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -31.32% per trade.
---